Asston Pharmaceuticals' board approved a preferential issue of 24.10 lakh shares at ₹115 each, aiming to raise ₹27.72 crore. An EGM is scheduled for July 31, 2026, for shareholder approval, impacting EPS and equity distribution.
Asston Pharmaceuticals Ltd Approves Preferential Issue
Key Highlights:
- Proposed Shares: 24,10,431 equity shares
- Issue Price: ₹115 per share
- Total Value: ₹27.72 crore
- EGM Date: July 31, 2026
What just happened
Asston Pharmaceuticals' Board of Directors has approved the issuance of 24,10,431 equity shares to non-promoter entities. The shares will be issued at ₹115 each, comprising a face value of ₹10 and a premium of ₹105. This preferential issue is a cash transaction expected to raise approximately ₹27.72 crore.
Why this matters
This move signifies a key capital-raising initiative for Asston Pharmaceuticals. It will infuse cash into the company, but existing shareholders should be aware of potential equity dilution and its impact on earnings per share (EPS). The company needs shareholder approval at an upcoming EGM to proceed.
The backstory
Preferential issues are a common method for companies to raise capital quickly from selected investors, often at a premium to the market price. Asston Pharmaceuticals is utilizing this route for its capital needs.
What changes now
The company is now moving towards seeking shareholder consent. An Extraordinary General Meeting (EGM) is scheduled for July 31, 2026, to obtain the necessary approvals for the preferential share issuance. Post-approval, the company will allot the shares.
Risks to watch
Investors should monitor the outcome of the EGM. Key concerns include the potential impact on EPS due to increased share count and the eventual use of the raised funds, which management needs to disclose for clarity on future growth drivers.
Peer comparison
(Information not available in the filing)
Context metrics (time-bound)
- Proposed Share Count: 24,10,431 equity shares
- Issue Price: ₹115 per share
- Total Funds to be Raised: ₹27.72 crore
- EGM Date for Approval: July 31, 2026
What to track next
Investors should track the minutes of the EGM for the resolution's outcome and subsequent company announcements detailing the specific deployment of the ₹27.72 crore raised, as well as any changes in the shareholding pattern.